Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
Open Access
- 15 April 2001
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 84 (8) , 1036-1042
- https://doi.org/10.1054/bjoc.2001.1731
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaJournal of Clinical Oncology, 2000
- Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon α2a and tamoxifen in metastatic melanomaMelanoma Research, 1999
- Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic MelanomaJournal of Clinical Oncology, 1999
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2bJournal of Clinical Oncology, 1999
- Combination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic MelanomaJournal of Clinical Oncology, 1999
- Long-term outcome of treatment with dacarbazine, cisplatin, interferon-α and intravenous high dose interleukin-2 in poor risk melanoma patientsMelanoma Research, 1998
- Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2aBritish Journal of Cancer, 1998
- Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastasesThe Lancet, 1998
- The use of interferon-α in the treatment of cutaneous melanomaMelanoma Research, 1998